THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the imminent submission of
a Marketing Authorization Application to the European Medicines Agency for
teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the
insulin-like growth factor-1 receptor, for the treatment of moderate to severe
Thyroid Eye Disease in adults. The company noted that, if approved, teprotumumab
would be the first and only medicine approved for TED in the European Union.

Teprotumumab is approved for TED in the U.S., Brazil and the Kingdom of Saudi
Arabia under the brand name TEPEZZA.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX